135 related articles for article (PubMed ID: 26990482)
1. C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.
Alkeraye S; Dadban A; Lok C; Arnault JP; Chaby G
Dermatol Online J; 2016 Jan; 22(1):. PubMed ID: 26990482
[TBL] [Abstract][Full Text] [Related]
2. A potential role for nilotinib in KIT-mutated melanoma.
Tran A; Tawbi HA
Expert Opin Investig Drugs; 2012 Jun; 21(6):861-9. PubMed ID: 22500535
[TBL] [Abstract][Full Text] [Related]
3. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
4. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Guo J; Carvajal RD; Dummer R; Hauschild A; Daud A; Bastian BC; Markovic SN; Queirolo P; Arance A; Berking C; Camargo V; Herchenhorn D; Petrella TM; Schadendorf D; Sharfman W; Testori A; Novick S; Hertle S; Nourry C; Chen Q; Hodi FS
Ann Oncol; 2017 Jun; 28(6):1380-1387. PubMed ID: 28327988
[TBL] [Abstract][Full Text] [Related]
6. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
8. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
9. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Lee SJ; Kim TM; Kim YJ; Jang KT; Lee HJ; Lee SN; Ahn MS; Hwang IG; Lee S; Lee MH; Lee J
Oncologist; 2015 Nov; 20(11):1312-9. PubMed ID: 26424760
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.
Cho JH; Kim KM; Kwon M; Kim JH; Lee J
Invest New Drugs; 2012 Oct; 30(5):2008-14. PubMed ID: 22068222
[TBL] [Abstract][Full Text] [Related]
11. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
12. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
13. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
Todd JR; Becker TM; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
[TBL] [Abstract][Full Text] [Related]
14. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
Murer C; Kränzlin-Stieger P; French LE; Dummer R; Goldinger SM
Melanoma Res; 2017 Aug; 27(4):396-398. PubMed ID: 28410286
[TBL] [Abstract][Full Text] [Related]
16. The GIST of targeted therapy for malignant melanoma.
Bello DM; Dematteo RP; Ariyan CE
Ann Surg Oncol; 2014 Jun; 21(6):2059-67. PubMed ID: 24531699
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Carvajal RD; Lawrence DP; Weber JS; Gajewski TF; Gonzalez R; Lutzky J; O'Day SJ; Hamid O; Wolchok JD; Chapman PB; Sullivan RJ; Teitcher JB; Ramaiya N; Giobbie-Hurder A; Antonescu CR; Heinrich MC; Bastian BC; Corless CL; Fletcher JA; Hodi FS
Clin Cancer Res; 2015 May; 21(10):2289-96. PubMed ID: 25695690
[TBL] [Abstract][Full Text] [Related]
18. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
19. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J; Chevret S; Jouary T; Dalac S; Dalle S; Guillot B; Arnault JP; Avril MF; Bedane C; Bens G; Pham-Ledard A; Mansard S; Grange F; Machet L; Meyer N; Legoupil D; Saiag P; Idir Z; Renault V; Deleuze JF; Hindie E; Battistella M; Dumaz N; Mourah S; Lebbe C;
J Invest Dermatol; 2018 Jan; 138(1):58-67. PubMed ID: 28843487
[TBL] [Abstract][Full Text] [Related]
20. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours.
Pantaleo MA; Nannini M; Saponara M; Gnocchi C; Di Scioscio V; Lolli C; Catena F; Astolfi A; Di Battista M; Biasco G;
Anticancer Drugs; 2012 Jun; 23(5):567-72. PubMed ID: 22430048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
